Zebinix regulatory update

Bial-Portela said EMA accepted for review an application to expand the label of Zebinix eslicarbazepine acetate to include its use as a once-daily monotherapy to treat newly diagnosed partial-onset epilepsy in adults. The voltage-gated sodium and T-type calcium channel blocker is approved in Europe as adjunctive therapy to treat partial-onset seizures. ...